Skip to main content
Eytan Stein, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

EytanMosheSteinMD

Oncology New York, NY

Hematologic Oncology

Physician

Dr. Stein is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Stein's full profile

Already have an account?

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 2010 - 2013
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2007 - 2010
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityClass of 2007

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2020 - Present
  • NJ State Medical License
    NJ State Medical License 2018 - 2023
  • NY State Medical License
    NY State Medical License 2010 - 2023
  • IL State Medical License
    IL State Medical License 2007 - 2010
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance  
    E Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
  • Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor Enasidenib  
    Eytan Stein, MD, Nature
  • Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
    Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
  • Join now to see all

Abstracts/Posters

  • RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
    Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propen...
    Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
    Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Use of Molecular Medicine to Assess Pretreatment Prognosis of Myeloid Disorders 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
  • Adult Clinical Malignant Hematology 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • CStone Successfully Hosted the First U.S. R&D Day in New York
    CStone Successfully Hosted the First U.S. R&D Day in New YorkJanuary 23rd, 2020
  • Finding the Optimal Treatment for IDH2-Mutated AML: Results of the BEAT AML Master Trial
    Finding the Optimal Treatment for IDH2-Mutated AML: Results of the BEAT AML Master TrialJanuary 11th, 2019
  • Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting
    Agios to Present Updated Clinical Data at the 2018 ASH Annual MeetingNovember 1st, 2018
  • Join now to see all

Hospital Affiliations